title: Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS.
authors: Department of Internal Medicine, Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany.
authors: H
authors: H
authors: Bertz
authors: Department of Internal Medicine, Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany.
authors: M
authors: M
authors: Lübbert
authors: Institute for Medical Biometry and Statistics, Freiburg University, Freiburg, Germany.
authors: K
authors: K
authors: Ohneberg
authors: Department of Internal Medicine, Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany.
authors: R
authors: R
authors: Zeiser
authors: Department of Internal Medicine, Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany.
authors: R
authors: R
authors: Wäsch
authors: Department of Internal Medicine, Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany.
authors: R
authors: R
authors: Marks
authors: Department of Internal Medicine, Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany.
authors: J
authors: J
authors: Finke
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000628:therapy*; D012008:Recurrence; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating